POSSIBLE WAYS TO INCREASE EFFECTIVENESS OF REPERFUSION THERAPY
Abstract
Possible ways to increase effectiveness of reperfusion therapy.
About the Authors
I. V. Ilienko
Российский государственный медицинский университет
Russian Federation
Russian Federation
N. A. Volov
Российский государственный медицинский университет
Russian Federation
Russian Federation
References
1. Тихазе А.К., Панкин В.З., Жарова Е.А., Колычева С.В. Триметазидин как антиокисидант непрямого действия. Биохим. биофиз. 2000; 130(10): 395-398.
2. Antman E.M. Magnesium in acute MI: Timing is critical. Circulation. 92: 2367: 1995.
3. Apstein C.S. Glucose-insulin-potassium for acute myocardial infarction. Remarkable results from a new, prospective randomized trial. Circulation. 1998; 98: 2223-2226.
4. Apstein C.S., Gravino F.N., Haudenschild C.C. Determinations of a prospective effect of glucose and insulin on the ischaemic myocardium: effects on contractile function, diastolic compliance, metabolism and ultrastructure during ischaemia and reperfusion. Circ. Res. 1983; 52: 515-526.
5. Arsenian M.A. Magnesium and cardiovascular disease. Prog. Cardiovasc. Dis. 1993; 35: 271.
6. Arsenian M., New P.S., Cafasso C.M. Safety, tolerability and efficacy of a glucose-insulin-potassium-magnesium-carnitine solution in acute myocardial infarction. Am. J. Cardiol. 1996; 78: 476-479.
7. Barron H.V., Bowlby L.J., Breen T., et al. For the National registry of myocardial infarction 2 investigators. Circulation. 1998; 97: 1150-1156.
8. Beltcher P.R., Dracke-Holland A.J., Hung J.W., et al. Effect of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc. Drugs Ther. 1993; 7: 149-57.
9. Boddeke E., Hugtenburg J., Jap W., et al. New anti-ischaemic drugs; cytoprotective action with no primary haemodynamic effects. Trends Pharm. Sci. 1989; 10: 397-400].
10. Bolli R. Oxygen-derived free radicals and postischaemic myocardial dysfunction ("stunned myocardium"). J. Am. Coll. Cardiol. 1988; 12: 239.
11. Chamberlain D. beta-blockers and calcium antagonists. In Julian D. and E. Braunwald (eds). Management in Acute Myocardial Infarction. London, W.B. Saunders Ltd., 1994, P193.
12. Detry J.M., Leclercq P.J. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am. J. Cardiol. 1995; 76: 8B-11B.
13. Detry J.M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Group. Br. J. Clin. Pharmacol. 1994; 37: 279-88.
14. Diaz R., Paolasso E.C., Piegas L.S., et al. on behalf of the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Metabolic modulation of Acute Myocardial Infarction. The ECLA Glucose-insulin-potassium pilot trial. Circulation. 1998; 98: 2227-2234.
15. The EMIP-FR Group: Effect of 48-h intravenous trimetazidine on short-and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. Eur. Heart. J. 2000; 21: 1537-1546.
16. Fath-Ordoubati F., Beatt K.J. Glucose-insulin-potassium (GIK) therapy for treatment of acute myocardial infarction: overview of randomized placebo-controlled trials. Circulation. 1997; 96: 1152-1156.
17. Fibrinolytic Therapy Trialists (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994; 343: 311.
18. Flink E.B., Brick J.E., Shane S.R. Alterations of long-chain free acid and magnesium concentrations in acute myocardial infarction. Arch. Intern. Med. 1981; 141: 441.
19. Grander C.B. Adenosine for myocardial protection in acute myocardial infarction. Am.J. Cardiol. 1997; 79: 44-8.
20. Gresh B.J., Anderson J.L. Thrombolysis snd myocardial salvage: Results of clinical trials and the animal paradigm -paradoxical or predictable? Circulation. 88: 296, 1993.
21. Gruppo Italiano per lo Studio della Sopravvivensa nell'Infarto Miocardico: GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343: 1115.
22. Guarniery C., Giordano E., Muscary С., et al. Vitamin E can protect myocardium against oxidative damage. Cardiovasc. Res. 1995; 30: 153.
23. Horowitz L.D., Gorlin R., Taylor M.J., et al. Effects of nitroglycerin in regional myocardial flow in coronary artery disease.J. Clin. Invest. 50: 1578, 1971.
24. В. Jugdutt, J. Warnica, Lancet. 1988; 1: 1088.
25. ISIS-4 Collaborative Group: ISIS-4: A randomized fractional trial assessing early oral captoprile, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet. 1995; 345: 669.
26. Karila-Colen D., Juliard J.M., Steg P.G. Is the "early hasard" related to TIMI-2 patients. Eur. Heart. J. 1997; 18 (Suppl.): 280 (abstract).
27. King L., Boucher F., Opie L.H. Coronary flow and glucose delivery as determinations of contracture in the ischaemic myocardium. J. Mol. Cell. Cardiol. 1995; 27: 701-725.
28. Klein H.H. Vitamin E cannot protect myocardium against oxidative damage. Cardiovasc. Res. 1995; 30: 156.
29. Klein H.H., Pich S., Bohle R.M., et al. Myocardial protection by Na+/H+ exchange inhibition in ischaemic, reperfused porcine heart. Circulation. 1995; 92: 912.
30. Kloner R.A., Ganote C.E., Jenings R.B., The "no-reflow" phenomenon after temporary coronary occlusion in the dog.J. Clin. Invest. 1974; 54: 1496-508.
31. Kober G., Buck T., Sievert H., Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur. Heart. J. 1992; 13: 1109-15.
32. Latini R., Maggioni A.P., Flather M., et al. "ACE-inhibitors use in patients with myocardial infarction": Summary of evidence from clinical trials. Circulation. 1995; 32: 3132.
33. Letters to editor. M Marzilli, et al. Eur. Heart J. Vol. 22, Iss. 11, June 2001. p. 973-978.
34. Liu B., el Alaoui-Talibi Z., Clanachan A.S., et al. Uncoupling of contractile function from mitochondrial TCA cycle activity and MV02 during reperfusion of ischaemic heart in rats. Am. J. Phisiol. 1996; 270: H72-H8.
35. Lopaschuk G.D. Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart disease. Eur. Heart. J. 1999; 1 Suppl. 0: 032-039.
36. Lopaschuk G.D. Treating ischaemic heart disease by pharmacologically improving cardiac energy metabolism. Am.J. Cardiol. 1998; 82: 14K-17K.
37. Lopaschuk G.D., Kozak R. Trimetazidine inhibits fatty acids oxidation in the heart.J. Mol. Cell. Cardiol. 1998; 30: A112.
38. Loscolzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am.J. Cardiol. 1992; 70: 18B.
39. The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction: Enzymatic estimation of infarct size. Am. J. Cardiol. 1985; 56: 27G.
40. Mahaffey K.W., Puma J.A., Barbagelata A., et al. Does adenosine in conjunction with thrombolysis reduce infarct size? Results from a controlled, randomized AMISTAD trial. Circulation. 1997; 96 Suppl. I: 1-206.
41. Malmberg K., Ryden L., Hamsten A., Herlits J., Waldenstrom A., Weden H. Effects of insuline treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI study group. Diabetes-Insulin-Glucose in Acute Myocardial Infarction. Eur. HeartJ. 1996; 17: 1337-1344.
42. Maridonneau-Parini I., Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br. J. Clin. Pharmacol. 1985; 20: 148-51.
43. Maridonneau-Parini I., Harpey C. Trimetazidine protects the human red blood cells against oxygen free radical damage. Cardiovasc. Drugs Ther. 1993; 4 Suppl. 4: 818-9].
44. Maroko P.R., Braunwald E. Modification of myocardial infarct size after coronary occlusion. Ann. Intern. Med. 1973; 79: 720.
45. Meneveau N., Knalife K., Louis J., et al. Free radicals, thrombolytic therapy and myocardial infarction: results of the EMIP-FR angiography substudy. Eur. Heart. J. 1997; 18: 171.
46. Mueller H.S., Ayres S.M. The role of propranolol in threatened of acute myocardial infarction. Prog Cardiovasc Dis. 1977; 19: 405.
47. Neuman F-j, Ott I., Gawaz M., et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995; 92: 748.
48. Noble M.I., Belcher P.R., Dracke-Holland A.J. Limitation of infarct size by trimetazidine in rabbit. Am.J. Cardiol. 1995; 76: 41B-44B.
49. Neumann F.J., Blasini R., Schitt С., et al. Effect of glycoprotein 11b/111a receptor blockade on recovery coronary flow and left ventricle function after placement coronary artery stents in acute myocardial infarction. Circulation. 1998; 98: 2695-701.
50. Norris R.M., Clarke E.D., Sammel N.L., et al. Protective effect of propranolol in threatened of myocardial infarction. Lancet 2: 907, 1978.
51. Oliver M.F., Opie L.H. Effects of glucose and fatty acids on myocardial ischaemia and arrythmias. Lancet. 1994; 343: 155-158.
52. Opie L.H. Glucose and the metabolism of ischaemic myocardium. Lancet. 1995; 345: 1520.
53. Opie L.H. Metabolism of fatty acids, glucose and catechoamines in acute myocardial infarction. Am. J. Cardiol. 1975; 36: 938-953.
54. Paradopoulos C.L., Kanonidis I.E., Kortidis P.S., et al. The effect of trimetazidine on reperfusion arrythmias in acute myocardial infarction. Int. J. Cardiol. 1996; 55: 137-42.
55. Pfeffer M. ACE inhibition in acute myocardial infarction. N. Engl. J. Med. 1995; 332: 118.
56. Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina. Cardiovasc. Drugs Ther. 1990; 4 Suppl. 4: 822-3.
57. Smalling R.W., Feld S., Ramanna N., et al. Infarct salvage with liposomal prostaglandin El administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation. 1995; 92: 935.
58. Sleight P., for the ISIS Study Group. Beta-blockade early in acute myocardial infarction. Am.J. Cardiol. 1987; 60: 6A-12A.
59. Steg P.G., Grollier G., Gallay P., et al. A randomized double-blind trial of trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Evidence for improved myocardial reperfusion from ST-segment analysis. Eur. Heart J. 1998; 19: 365 (abstract).
60. Stenley W.C., Lopaschuk G.D., Hall J.L., McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardivasc. Res. 1997; 33: 243-257.
61. Sentex E., Sergiel J.P., Lusien A., Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocytes. Mol Cell Biochem. 1997; 175: 153-162.
62. Sun D., Nguen N., DeGrado T.J., et al. Ischaemia induces translocation of the insulin-responsive glucose transporter GLUT 4 to the plasma membrane of cardiac myocytes. Circulation. 1994; 89: 793-898.
63. Taegtmeyer H. Energy metabolism of the heart: From the concepts to clinical applications. Curr. Probl. Cardiol. 1997; 19: 57.
64. Teo K.K., Yusuf S. Role of magnesium in reducing mortality in acute myocardial infarction: A review of the evidence. Drugs 1993; 46: 347.
65. Waagstain F., Hjalmaarson A.C. Double-blind study of the effect of cardioselective beta-blockade on chest pain in acute myocardial infarction. Acta Med. Scand. 1975; 587 (Suppl): 201.
66. Williams F.M., Tanda K., Kus M., Williams T.J. Trimetazidine inhibits neutrophil accumulation in the rabbits. J. Cardiovasc. Pharmocol 1993; 22: 828-33.
67. Woods K.L. Possible pharmacological actions of magnesium in acute myocardial infarction. Br. J. Clin. Pharmacol. 1991; 32: 3.
68. Woods K.L., Fletche S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: The second Leicester Intravenous Magnesium Intervention Trial (LIMI-2). Lancet. 1994; 343: 816.
69. Yusuf S., Wttes J., Friedman L. Overview of results of randomized clinical trials in heart disease.I. Treatments following myocardial infarction. JAMA. 1988; 260: 2088.
Review
For citations:
Ilienko I.V., Volov N.A. POSSIBLE WAYS TO INCREASE EFFECTIVENESS OF REPERFUSION THERAPY. Russian Journal of Cardiology. 2003;(5):83-88. (In Russ.)
Views:
281
Email this article 